A rare disease reveals a hidden flaw in the immune system
Researchers found a defect in natural killer (NK) cells, a problem that had been underrecognized in mevalonate kinase deficiency (MKD). For about 30 years, research had mainly focused on macrophages, immune cells involved in coordinating inflammation. The new findings suggest NK-cell dysfunction is central to the disease, rather than macrophage activity alone. In people with MKD, NK cells do not mature properly and struggle to destroy infected cells. Their toxic granules, which normally help kill targets, remain trapped inside the cells. When NK cells fail to clear a target, they release large amounts of interferon gamma, an inflammatory signal that activates other immune cells. This misfiring can contribute to the dangerous fevers and widespread inflammation seen during MKD attacks. The discovery points to JAK inhibitors or other drugs that neutralize interferon gamma as possible treatment options. The researchers say clinical studies are needed to explore these approaches, especially for patients who do not respond adequately to current treatments.
What previously overlooked problem did researchers find in the immune systems of people with MKD?
Researchers found a defect in natural killer (NK) cells, a problem that had been underrecognized in mevalonate kinase deficiency (MKD). For about 30 years, research had mainly focused on macrophages, immune cells involved in coordinating inflammation. The new findings suggest NK-cell dysfunction is central to the disease, rather than macrophage activity alone.
In people with MKD, NK cells do not mature properly and struggle to destroy infected cells. Their toxic granules, which normally help kill targets, remain trapped inside the cells. When NK cells fail to clear a target, they release large amounts of interferon gamma, an inflammatory signal that activates other immune cells.
This misfiring can contribute to the dangerous fevers and widespread inflammation seen during MKD attacks. The discovery points to JAK inhibitors or other drugs that neutralize interferon gamma as possible treatment options. The researchers say clinical studies are needed to explore these approaches, especially for patients who do not respond adequately to current treatments.
What is mevalonate kinase deficiency (MKD), and what kinds of symptoms can it cause?
Mevalonate kinase deficiency, or MKD, is a rare, lifelong genetic condition. It affects hundreds of children and adults around the world, and researchers suspect that some people with it have never been diagnosed. The condition can cause recurring inflammatory attacks, which may be severe and sometimes life-threatening.
During attacks, patients can develop high fever, skin rashes, joint pain, and inflammation in the abdomen. The article links dangerous episodes to the immune system’s response when infections occur. It reports that malfunctioning natural killer cells can fail to eliminate infected cells and release large amounts of the inflammatory signal interferon gamma.
Current treatments are designed to block an inflammatory signal released by macrophages, but roughly half of patients do not respond adequately. The new findings suggest another part of the immune system may be involved. Researchers say the work could lead to clinical studies of JAK inhibitors or other drugs that neutralize interferon gamma, although those options need further investigation.
How do natural killer (NK) cells normally help the body fight infections?
Natural killer cells, often called NK cells, are immune cells that help the body eliminate infected cells. The article describes them as part of the body’s early defenses against viral infections. Their job is important because removing infected targets can help stop an infection from spreading.
NK cells carry toxic material in granules. When functioning properly, they release these granules to kill infected cells. The researchers found that in MKD, NK cells may fail to mature correctly and cannot release their granules effectively. That means they struggle to perform this key infection-fighting role.
The study also highlights what happens when this defense fails: the NK cells can release large amounts of interferon gamma instead. This signal activates other immune cells and can drive inflammation. The findings therefore connect NK cells’ normal role in clearing infected cells with the excessive inflammatory response observed in MKD. They do not change the basic job of NK cells; they reveal how their malfunction may contribute to disease.
What can happen when MKD-affected NK cells cannot release their granules and destroy infected cells?
In MKD, natural killer cells can have trouble releasing the toxic granules they use to destroy infected targets. If they cannot kill those targets, the immune system may not clear an infection effectively. The researchers connect this failed cell-killing function with the serious inflammatory symptoms of the disorder.
The team’s explanation is that a struggling NK cell compensates by sending out large amounts of interferon gamma. This is a powerful inflammatory signal. It activates other immune cells, and the response can spread beyond the original target. The article describes this as the cell “shouting for help” when it cannot do its usual job.
The result can be dangerous fever and widespread inflammation during MKD attacks. The findings came from blood samples from people with MKD and preclinical models. They also point to a possible new treatment strategy: JAK inhibitors or other drugs that neutralize interferon gamma. Researchers say clinical studies are needed to test these possibilities.
How many people are known to be affected by MKD, and how many patients may not respond well to current treatments?
The article says MKD is known to affect hundreds of children and adults around the world. Researchers suspect that many people with the disorder have never been diagnosed, so the known number may not capture everyone affected. It does not give a precise total for diagnosed patients.
The treatment gap is also substantial: approximately half of patients do not respond adequately to current therapies. Those existing treatments are designed to block an inflammatory signal released by macrophages. When treatment does not work well, patients remain in need of better options for a condition that can cause recurring attacks and, in the most serious episodes, potentially fatal complications.
The new research may help address that gap by identifying malfunctioning natural killer cells and excess interferon gamma as additional targets. Researchers suggest exploring JAK inhibitors or other drugs that neutralize interferon gamma in future clinical studies. The article does not report a new approved treatment or give a more exact patient count.
How does the new finding challenge the long-held idea that macrophages are the main drivers of MKD inflammation?
For roughly three decades, research into MKD largely centered on macrophages, immune cells that help coordinate the body’s inflammatory defenses. Existing treatments were designed around this explanation, targeting an inflammatory signal released by macrophages. But about half of patients do not respond adequately, leaving an important need for better options.
The Garvan team examined blood samples from people with MKD and studied preclinical models. They found that natural killer cells fail to mature properly and struggle to destroy infected cells. When they cannot do so, they can release large amounts of interferon gamma, which activates other immune cells and may drive widespread inflammation.
The findings challenge the idea that macrophage activity alone is the main explanation for MKD inflammation. The researchers say the primary problem may lie in NK cells. This shifts the disease model and suggests possible new treatment targets, including JAK inhibitors or drugs that neutralize interferon gamma. Clinical studies would be needed to explore these approaches.
How can immune signals such as interferon gamma help defend the body but also cause harm when too much is released?
The article describes interferon gamma as a powerful inflammatory signal. In the setting studied, it activates other immune cells when natural killer cells fail to destroy their targets. That activation is part of the immune system’s response to a problem, but the article shows how an excessive signal can become harmful.
In MKD, NK cells can have toxic granules trapped inside them and struggle to kill infected cells. Professor Mike Rogers says they compensate by releasing large amounts of interferon gamma. Instead of clearing the target, the malfunctioning cells effectively call for help, prompting other parts of the immune system to become active.
When this response becomes excessive, it can contribute to dangerous fever and widespread inflammation. The study identifies interferon gamma as a possible target for future treatment, including drugs that neutralize it. The researchers also point to JAK inhibitors, but say future clinical studies are needed to explore these options in people with MKD.
This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.
Read more in the JupiteX app
Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.
Or read more news on the web